AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03999554 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LD Bris10 M2SR H3N2 influenza vaccine
Description: This group will receive a low dose of the Bris10 M2SR H3N2 monovalent influenza vaccine administered intranasally.
Study NCT03999554 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive saline placebo administered intranasally.
Study NCT02008175 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional CXL
Description: Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin (\<0.1%) to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/cm2 with riboflavin and distilled water alternated every 2 minutes was used for the procedure..
Study NCT04693455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD03
Description: ZD03 capsule
Study NCT04693455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule
Study NCT03780790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: % 0,25
Study NCT01631110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
Study NCT02148159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cachexia Acupuncture-A (Peace Classic Needles® )
Description: Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points.
Study NCT02148159 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: General Acupuncture-B (Peace Classic Needles®)
Description: Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points.
Study NCT03172169 — intervention group
Intervention type: OTHER
Intervention: no Intervention
Description: no Intervention
Study NCT03227185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real anodal transcranial direct current stimulation (tDCS)
Description: The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
Study NCT03227185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham transcranial direct current stimulation (tDCS)
Description: The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
Study NCT03582878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus Oral Product
Description: Oral form of sirolimus, daily dosing to achieve target trough levels between 5-10ng/ml since 1.day of transplantation
Study NCT03582878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil dosing 1g before transplantation and 1g bid afterwards
Study NCT03534362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasopore
Description: Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent applied to the post-operative outflow tract
Study NCT03534362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Propel
Description: Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement applied to the post-operative outflow tract.
Study NCT03992014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linerixibat tablet
Description: Linerixibat will be available as white to slightly colored film-coated round tablet to be administered as two tablets taken in the fasted state in the morning with 240 milliliter (mL) of room temperature water.
Study NCT03992014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-linerixibat intravenous infusion
Description: \[14C\]-linerixibat will be available as clear, colorless solution free from visible particulates to be administered 25 mL IV over 3 hours immediately after the oral dose.
Study NCT03992014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linerixibat oral solution
Description: Linerixibat will be available as clear, colorless solution free from visible particulates to be administered 60 mL solution in the fasted state in the morning.
Study NCT01597531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily.
Study NCT01597531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Orlistat will be started initially at a dose of 60 mg taken with the evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day and the patients will be advised to take a multivitamin 2 hours before or after Orlistat addition to ensure adequate nutrition.
Study NCT01597531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide + Orlistat
Description: Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily. Patients not tolerating a higher dose will be allowed to remain on the lower dose as long they tolerate the lower. Following titration of Liraglutide to a maximum tolerated dose, Orlistat will be started initially at a dose of 60 mg taken with evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day.
Study NCT02047383 — intervention group
Intervention type: OTHER
Intervention: Respiratory infection
Description: An assessment of the patients included in the study will be conducted
Study NCT02437383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol ER
Description: Capsules given orally according to schedule at Visit 1, Visit 2, Visit 3, and Visit 4.
Study NCT02437383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules with a microcrystalline cellulose filler manufactured to mimic propranolol ER 60 mg capsules
Study NCT01842100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Universal antibiotic prophylaxis
Description: 100 mg twice daily for 7 days starting on the day of induced abortion
Study NCT01842100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screen-and-treat
Description: Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.
Study NCT01963273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video Assisted Ablation of Pilonidal Sinus
Study NCT01374828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketolorac
Description: Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.
Study NCT02403856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
Study NCT02403856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone acetate
Description: Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
Study NCT02403856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Needling and Lavage
Study NCT02403856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Needling and Lavage
Study NCT00480883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meglumine antimoniate, allopurinol
Description: first drug in injectable, second is in tablet form.
Study NCT00480883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meglumine antimoniate
Description: injectable 20 mg/kg/day/intramuscular for 21 days.
Study NCT00480883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meglumine antimoniate, allopurinol
Description: injectable meglumine antimoniate 10 mg/kg/day/intramuscular for 21 days plus tablet allopurinol 300mg/4times a day for 21 days.
Study NCT01880281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meat and vegetable diet
Description: After having a diet of 3 days and the investigational's day, the volunteers will have the other diet
Study NCT03380715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal nebulisation into the right nostril
Description: 400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
Study NCT03380715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Spray into the right nostril
Description: Intervention : Administration of 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity using a nasal spray and subsequently checking nasal resistance post nasal spray
Study NCT01744873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol Fumarate Tablet 10 mg
Description: 10 mg tablet once a day
Study NCT01744873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: 10 mg tablet once a day
Study NCT02234232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.
Study NCT02234232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.
Study NCT01330030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline
Description: 6mg/24 hrs for 8 weeks
Study NCT01330030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: placebo/24hrs for 8 weeks
Study NCT02410551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: 200 mg by mouth twice a day for 60 days.
Study NCT04304534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2433334
Description: Tablet, taken orally once a day.
Study NCT02410551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.
Study NCT02410551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.
Study NCT02410551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Phone calls made by study staff to participant on second and third week of each month.
Study NCT02410551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.
Study NCT02410551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
Study NCT02104869 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (inactivated and fragmented).
Study NCT02104869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (inactivated and fragmented).
Study NCT04622124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04622124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fasted vs. high-fat meal
Study NCT02663882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self control practice - smoking related task
Description: participants will be asked to practice a smoking-related self control task for 7 days: they will be asked to resist smoking when they have cravings as much as possible during the day
Study NCT02663882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self control practice - non-smoking related task
Description: participants will be asked to practice a non-smoking-related self control task for 7 days: they will be asked to keep a straight posture as much as possible during the day
Study NCT00122447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 325 mg PO QD
Study NCT00122447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid
Description: 600 mg PO BID
Study NCT00122447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: 40 mg PO QD
Study NCT00122447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo for each active comparator:~placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD
Study NCT01279382 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hypnotherapy (HYP)
Description: Hypnotherapy was given to a subgroup of patients as intervention in IBS treatment
Study NCT01279382 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation training (RT)
Description: RT was given to a subgroup of patients as intervention in IBS treatment
Study NCT01279382 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care as usual (CON)
Description: CON was given to a subgroup of patients as control intervention in IBS treatment
Study NCT04360408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis
Description: The total program consisting of three educational sessions (at Week -1, week -3 and week -5) and one booster session (week -10) over a period of 12 weeks. Participants will receive individual, face to face education during their regular HD session. Education will be provided over 30-45 minutes for the first session, 30 minutes in the next two sessions and 30-45 minutes for the booster session. The lead researcher, who is a nurse, will deliver the entire intervention to avoid information bias. The simple language will be used, and emphasis will be given on the objectives of each session.
Study NCT00361478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and education
Description: Weekly exercise and education program for 8 weeks
Study NCT00361478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Written educational material
Study NCT02959008 — intervention group
Intervention type: DEVICE
Intervention: measure TOI and BP
Description: Both groups measure TOI and BP.
Study NCT03749954 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detachable string magnetically controlled capsule endoscopy
Description: Esophagogastroduodenoscopy is performed 2 hours after the magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
Study NCT00117806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 1
Description: SCI-VIP: Supported employment implemented for veterans with spinal cord injury.
Study NCT00117806 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Arm 2
Description: Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
Study NCT04114942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Never Coach
Description: 20 weeks of didactic training and 10 weeks of internship, but no coaching.
Study NCT04114942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internship Only Coach
Description: 20 weeks of didactic training with no coaching and 10 weeks of internship with coaching.
Study NCT01419626 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Interdental cleaning device with water
Description: Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
Study NCT01419626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interdental cleaning device with essential-oil mouthrinse
Description: Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
Study NCT03123367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Nella VuSleeve
Description: Sleeve
Study NCT03123367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Nella NuSpec
Description: Speculum
Study NCT03123367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 3: NellaSpec
Description: Speculum
Study NCT03123367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 4: Nella Insert
Description: Sleeve
Study NCT04610385 — intervention group
Intervention type: PROCEDURE
Intervention: radical cystectomy with urinary diversion
Description: surgical removal of the urinary bladder and other organs and perform a urinary shunt
Study NCT04137627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 20 MG Oral Capsule
Description: The administration of Melatonin 20 mg in addition to neoadjuvant chemotherapy to observe the antioxidant and onco-static effect.
Study NCT04137627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The administration of placebo capsule in addition to neoadjuvant chemotherapy
Study NCT02053870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy+conventional treatment
Description: Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
Study NCT02053870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
Study NCT02609828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
Study NCT02609828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tanezumab
Description: Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
Study NCT00963222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A
Description: 1 cap vitamin A 25000 IU/day for 3 month
Study NCT00963222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 cap placebo/day for 3 month
Study NCT04553679 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mindfulness online intervention
Description: A 3-week mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
Study NCT00333840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib mesilate
Description: imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
Study NCT00333840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesilate
Description: imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
Study NCT00333840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon-alpha (INF-a)
Description: interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day.
Study NCT03421353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150 will be administered as a 1-hour intravenous infusion either weekly (QW) or every two weeks (Q2W), depending on which arm the patient is enrolled in.~AZD9150 will be provided as a liquid drug product in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement.